Two hundred sixty‐five wild‐type IDH GBM patients without antecedent history of low‐grade glioma were diagnosed as having primary GBMs (gross‐total resection rate: 72.6%, subtotal resection rate: 27.4%, 176 patients completed the above‐mentioned course of chemoradiation). The gene discussed is IDH2; the disease is central nervous system cancer.